Enliven Therapeutics, Inc. (ELVN) Cash Flow Statement
Enliven Therapeutics, Inc. (ELVN) generated -$66.9M of operating cash flow over the twelve months to 2026-06-30, spent $98000 on capital expenditure and had free cash flow of -$67.0M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ELVNEnliven Therapeutics, Inc.Follow ELVN — free
—
Price chart with a free account
- Market cap
- 3.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 25 days
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -37.4 | -46.8 | -32.1 | -61.3 | -73.2 | -70.3 | -66.9 | |
| Capital expenditure | 0.0 | 0.0 | 0.6 | 0.1 | 0.0 | 0.2 | -0.1 | |
| Free cash flow | -37.4 | -46.8 | -32.7 | -61.4 | -73.2 | -70.5 | -67.0 | |
| Stock-based compensation | 2.2 | 3.8 | 3.2 | 12.9 | 20.2 | 34.0 | — |
USD millions · SEC XBRL
Enliven Therapeutics, Inc. — questions
- What is Enliven Therapeutics, Inc.'s operating cash flow?
- -$66.9M over the twelve months to 2026-06-30.
- How much does Enliven Therapeutics, Inc. spend on capital expenditure?
- $98000 over the twelve months to 2026-06-30.
- What is Enliven Therapeutics, Inc.'s free cash flow?
- -$67.0M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Enliven Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.